FINDINGS:
Comparison: 2024-01-09.
Lungs: No focal consolidation or suspicious pulmonary nodules. No pneumothorax. lungs are normal.
Mediastinum: Enlarged paratracheal lymph node, short axis 12 mm. Cardiomediastinal contours within normal limits.
Pleura/Pleural spaces: No pleural effusion or pleural thickening.
Great vessels/Aorta: No thoracic aortic aneurysm or dissection.
Liver: No focal hepatic lesions. Normal attenuation. no hepatic mass.
Spleen: Normal in size and attenuation. No focal splenic lesion. spleen normal size.
Pancreas: 10.9 cm spiculated pancreatic mass in the tail of the pancreas (isoenhancing). Normal pancreatic contour and enhancement. No focal mass.
Adrenal glands: Adrenal glands are normal without nodules.
Kidneys: No hydronephrosis. No enhancing renal mass. no renal mass.
GI tract/Bowel: No obstructive process. No focal bowel wall mass identified.
Mesentery/Omentum: No ascites. No omental caking.
Mesenteric vessels (SMA/SMV): SMA/SMV are patent without thrombosis.
Urinary bladder: Unremarkable.
Reproductive organs: No adnexal mass. Uterus/prostate within expected size for age. BPH. ovaries are normal / no adnexal abnormality.
Lymph nodes: Enlarged celiac lymph node, short axis 29 mm. No pathologically enlarged lymph nodes by size criteria.
Bones/Osseous structures: No aggressive osseous lesion. No acute fracture.

IMPRESSION:
- Pancreas primary malignancy at tail of the pancreas measuring approximately 109 mm.
- Findings concerning for nodal involvement.
- No definite distant metastases identified.
- RECIST 1.1 Summary:
- Target lesions (n=2; ≤2 per organ rule applied).
  • T1: Primary — 79→109 mm (longest diameter).
  • T2: Lymph node — 23→29 mm (short axis).
- SLD baseline: 102 mm.
- SLD current: 138 mm (+35.3% change).
- New lesions: present (unequivocal).
- - RECIST 1.1 overall response category: PD.
